Neos Therapeutics Inc

Neos Therapeutics — Merger or Acquisition (December 2020)

19 slides from Neos Therapeutics's merger presentation, Dec 11, 2020

  1. Slide 1: Aytu BioScience to Acquire Neos Therapeutics, Inc.

    Aytu BioScience (NASDAQ: AYTU) Aytu BioScience to Acquire Neos Therapeutics, Inc. December 10, 2020 aytubio.com

  2. Slide 2: Transaction Highlights & Strategic Rationale

    Transaction Highlights & Strategic Rationale Transaction creates highly diversified specialty pharmaceutical company with $100mm of pro forma revenue Brand Marketing (10 products), Pediatric, Primary Care, and Consumer Healthcare products Accelerates transformation to profitability with estimated an

  3. Slide 3: Combination Overview

    Combination Overview (1) Announced and effective on December 8, 2020. (2) Based on the 10-day VWAP of Aytu stock as of 12/9/20

  4. Slide 4: Highly Diversified Specialty Pharmaceuticals Platform with $100 Million in Revenue

    Highly Diversified Specialty Pharmaceuticals Platform with $100 Million in Revenue Three Complementary Product Sets with Critical Mass in Pediatrics PediatricsPrimary CareConsumer Health As of September 30, 2020.

  5. Slide 5: Synergies will Create Robust Value and Expected to Drive Profitability

    Synergies will Create Robust Value and Expected to Drive Profitability Continued Opportunities for Synergies SG&A Commercial efficiencies Duplicative overhead Support functions and technology systems Operations Manufacturing optimization Streamlined R&D $15 Million Quick, efficient integration due t

  6. Slide 6: NEOS's ADHD Portfolio: A Market Expansion Opportunity

    NEOS’s ADHD Portfolio: A Market Expansion Opportunity Approved for patients 6+ years, both pediatric and adult Focused on adults – the fastest growing segment of the market Approved for patients ages 6-17 Compelling clinical efficacy data demonstrating symptom control at 1 hour after dosing and sust

  7. Slide 7: Large and Growing ADHD Market

    Large and Growing ADHD Market Drug Type Annual Prescriptions1 (Million) Annual Gross Revenue2 (Billion) Amphetamine 48.5 $5.6 Methylphenidate 19.6 $2.6 Non-Stimulants 6.9 $0.3 Total 75.1 $8.5 Adzenys XR-ODT launched in 2016 Cotempla XR-ODT launched in 2017 Adzenys ER launched in 2019 IQVIA: National

  8. Slide 8: Neos RxConnect Program Will Support and Grow Aytu's Heritage Brands

    Neos RxConnect Program Will Support and Grow Aytu’s Heritage Brands Offers predictability and enhances access to Neos brands for 100% of commercially insured patients, regardless of individual insurance coverage Allows prescribers to focus on best therapeutic option, rather than on individual insura

  9. Slide 9: New Product Opportunity Creates Future Growth

    New Product Opportunity Creates Future Growth NT0502 is in Phase 1 clinical development for the treatment of chronic sialorrhea (excessive drooling) Significant unmet need for an effective therapy with an improved tolerability profile and dosing regimen PrevalenceEst. Affected PatientsCurrent Therap

  10. Slide 10: Combined Companies Create Platform to Drive Growth and Support Acquisitions

    Combined Companies Create Platform to Drive Growth and Support Acquisitions Existing Portfolio Expected to Grow and Generate Cash Flow Ability to Accelerate Growth Through Smart Acquisitions Potential to Unlock Significant Shareholder Value Unique opportunity to acquire assets as a consolidator in a

  11. Slide 11: Experienced Executive Leadership

    Experienced Executive Leadership Josh Disbrow Chairman and CEO, Aytu BioScience Former VP of Commercial Operations at Arbor Pharmaceuticals; revenues grew from zero to over $127MM in < 5 years; Acquired by KKR Previous COO of Ampio Pharmaceuticals (NYSE: AMPE) and head of Business Unit Progressive c

  12. Slide 12: Transaction Next Steps

    Transaction Next Steps Announce Review Close Announce the deal and file merger agreement. Subject to customary review and closing requirements. Obtain shareholder approvals. Expected to close in the second quarter of 2021. Shares to be traded under Aytu Bioscience (AYTU) on the Nasdaq. 12

  13. Slide 13: Supplemental Information

    SUPPLEMENTAL INFORMATION 13

  14. Slide 14: Overview of Aytu BioScience

    Overview of Aytu BioScience Focus: Licenses/acquires and commercializes novel prescription and consumer health products competing in large markets Rx Products: Natesto, Tuzistra XR, ZolpiMist Consumer Health Products: Over 20 consumer brands Finances: $13.520m net product revenue (Q1 2021) $27.632m

  15. Slide 15: Overview of Neos Therapeutics

    Overview of Neos Therapeutics Focus: Develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform Products: Adzenys XR-ODT amphetamine, Cotempla XR-ODT methylphenidate; Adzenys ER amphetamine; and

  16. Slide 16: NT0502 Development Program

    NT0502 Development Program Phase 1 - Single and Multiple Ascending Dose Study Source: Neos Management

  17. Slide 17: Additional Information about the Proposed Merger Transaction and Where to Find It

    Additional Information about the Proposed Merger Transaction and Where to Find It This communication relates to the proposed merger transaction pursuant to the terms of the Agreement and Plan of Merger, dated as of December 9, 2020, by and among Neos Therapeutics, Inc. (“Neos”), Aytu Bioscience Inc.

  18. Slide 18: No Offer or Solicitation

    No Offer or Solicitation This communication does not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor a solicitation of any vote or approval with respect to the proposed merger transaction or otherwise. No offering of securities shall be made except by means o

  19. Slide 19: Contact Information

    Contact Information: Josh Disbrow Chief Executive Officer josh.disbrow@aytubio.com Investor Relations: James Carbonara Hayden IR james@haydenir.com Transfer Agent: Direct Transfer info@issuerdirect.com 877-481-4014 19

Neos Therapeutics — Merger or Acquisition (December 2020) on 6ix